Zhou Shu-Feng, Lai Xinsheng
School of Health Sciences, World Health Organization Collaborating Centre for Traditional Medicine, RMIT University, Bundoora, Victoria 3083, Australia.
Curr Drug Metab. 2008 Jun;9(5):394-409. doi: 10.2174/138920008784746391.
St. John's wort (Hypericum perforatum, SJW) is one of the most commonly used herbal antidepressants for the treatment of minor to moderate depression. Limited clinical trials suggest that hypericum and standard antidepressants have similar beneficial effects, but current evidence regarding the antidepression effects of SJW extracts is inconsistent. A major safety concern about SJW is its ability to alter the pharmacokinetics and/or clinical response of a variety of clinically important drugs. This review highlights and updates the knowledge regarding drug interactions with SJW by a systematic review of all the available evidence, including worldwide published literature and spontaneous case reports. A number of clinically significant interactions of SJW have been identified with conventional drugs. These interactions often result in a decrease in the concentration or effect of the combined drug, most probably due to the induction of cytochrome P450s (CYPs) and the key drug transporter P-glycoprotein (P-gp) by the major active constituents in SJW. SJW is a potent inducer of human CYP3A4 and P-gp in vitro and in vivo. In addition, pharmacodynamic interactions of SJW with some drugs (e.g. selective serotonin re-uptake inhibitors) have been identified, which are associated with an increased risk of adverse reactions. Since potential interactions of SJW with conventional drugs is a major safety concern, it is important to minimize and avoid these interactions by taking appropriate approaches. These include systematic research to identify SJW-drug interaction; close therapeutic drug monitoring when SJW is combined with conventional drugs with a narrow therapeutic window; proper dose and regimen adjustment; patient education and communication between the patient and physician; design of new preparations of SJW without inducing ability of CYP3A4 and P-gp while retaining its bioactivity; and appropriate regulation in herbal safety and efficacy. Further clinical and mechanistic studies are warranted to explore the interaction of SJW with other important drugs and clinical significance.
圣约翰草(贯叶连翘,SJW)是治疗轻至中度抑郁症最常用的草药抗抑郁药之一。有限的临床试验表明,贯叶连翘与标准抗抑郁药具有相似的有益效果,但目前关于SJW提取物抗抑郁作用的证据并不一致。对SJW的一个主要安全担忧是它改变多种临床重要药物药代动力学和/或临床反应的能力。本综述通过对所有现有证据进行系统评价,包括全球发表的文献和自发病例报告,突出并更新了关于SJW与药物相互作用的知识。已确定SJW与传统药物存在一些具有临床意义的相互作用。这些相互作用通常会导致联合用药的浓度或效果降低,最可能的原因是SJW中的主要活性成分诱导细胞色素P450(CYPs)和关键药物转运蛋白P-糖蛋白(P-gp)。SJW在体外和体内都是人CYP3A4和P-gp的强效诱导剂。此外,还确定了SJW与某些药物(如选择性5-羟色胺再摄取抑制剂)之间的药效学相互作用,这与不良反应风险增加有关。由于SJW与传统药物的潜在相互作用是一个主要的安全问题,因此通过采取适当方法尽量减少和避免这些相互作用非常重要。这些方法包括系统研究以确定SJW与药物的相互作用;当SJW与治疗窗较窄的传统药物联合使用时进行密切的治疗药物监测;适当调整剂量和用药方案;患者教育以及患者与医生之间的沟通;设计不具有CYP3A4和P-gp诱导能力但保留其生物活性的SJW新制剂;以及对草药安全性和有效性进行适当监管。有必要进行进一步的临床和机制研究,以探索SJW与其他重要药物的相互作用及其临床意义。